A Good AASLD Meeting Summary
This is a terrific overview article regarding the AASLD meeting. Liz Highleyman did a fantastic job of condensing the key... View Article
Continue reading »General Hepatitis C News/Updates
Shorter Therapy Effective for Genotypes 2 and 3
Genotypes 2 and 3 are much more responsive to current interferon combination therapies. This report details studies that show a... View Article
Continue reading »Pegasys Shown More Effective In Study
Schering and Roche are taking part in dueling press releases. Each claiming their solution is better. Either way, they seem... View Article
Continue reading »Weight-based Treatment of HCV
Weight-based dosing has always made sense to us. We don’t really understand why Roche has not changed their dosing to... View Article
Continue reading »Your Results May Vary For HCV Treatment
According to this study, actual treatment results may be only half as good as touted. Doctors tend to trust the... View Article
Continue reading »More HCV Treatment News Coverage
The Los Angeles Times is one of the largest daily newspapers in the U.S. Their interest in HCV is indicative of a growing awareness of the extent of the disease in this country. The article clearly focuses on the hope of safer, more effective treatments than what is now available.
Continue reading »A Good HCV Newspaper Article
This is one of the best general audience articles we’ve come across on HCV in quite a while. There is... View Article
Continue reading »Report Claims MOST HCV Patients Will Develop Cirrhosis
Sep 2, 2005
1 Comment
This is one of the most broad announcements regarding Hepatitis C I’ve seen in a long time. It appears to... View Article
Continue reading »Hepatitis A Vaccinations Highly Recommended
If you are a Hepatitis C patient and have not yet been vaccinated against Hepatitis A, you should be as... View Article
Continue reading »HCV Treatment and Obesity
Aug 4, 2005
1 Comment
This article contains quite a few tidbits of good information (in addition to the primary focus). The description of "signs" that a small number of patients have does a good job of covering possible symptoms and effects of the disease. It also seems that the main difference in success between Pegasys and Peg-Intron in these patients may have more to do with the difference in dosing between standard levels of medication and weight based dosing.
Continue reading »
